Who Paid My Doc
Christopher Chermansky
Urology Pittsburgh, PA Medical Doctor
NPI 1942307038 CMS profile 87912
300 Halket Street, Suite 2541, Pittsburgh, PA 15213
General payments
$10,673
Research payments
$5,399
Ownership & investment interest
$0
Research they led as principal investigator
$47,123
Through program year 2025, Christopher Chermansky of Pittsburgh, PA is reported in the CMS Open Payments database as having received $10,673 across 64 general payments and $5,399 in research payments paid to them. Separately, studies naming them as principal investigator received $47,123 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 87th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,568 | 5 | |
| 2024 | General | $355 | 4 | |
| 2023 | General | $2,287 | 20 | |
| 2022 | General | $462 | 7 | |
| 2021 | General | $137 | 5 | |
| 2020 | General | $213 | 4 | |
| 2020 | Research | $5,054 | 5 | |
| 2019 | General | $651 | 19 | |
| 2019 | Research | $345 | 1 |
Beside peers
- Christopher Chermansky
- Urology median
- Middle half of Urology
- National median
In program year 2025, general payments to Christopher Chermansky were reported at $6,568. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.
Show as a table
| Year | Christopher Chermansky | Urology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $651 | $480 | $147–$1,201 | $163 |
| 2020 | $213 | $246 | $87–$645 | $114 |
| 2021 | $137 | $358 | $111–$1,000 | $132 |
| 2022 | $462 | $476 | $143–$1,263 | $149 |
| 2023 | $2,287 | $560 | $168–$1,461 | $160 |
| 2024 | $355 | $563 | $170–$1,464 | $164 |
| 2025 | $6,568 | $629 | $190–$1,620 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
1,385
Drug cost
$454,271
Branded share of claims
70.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 405 | $252,316 | |
| Gemtesa Vibegron | Brand | 150 | $94,086 | |
| Mirabegron Er Mirabegron | Brand | 138 | $51,725 | |
| Trospium Chloride Er Trospium Chloride | Brand | 166 | $25,664 | |
| Premarin Estrogens, Conjugated | Brand | 17 | $7,254 | |
| Methenamine Hippurate | Generic | 80 | $6,820 | |
| Gentamicin Sulfate | Generic | 60 | $4,825 | |
| Solifenacin Succinate | Generic | 83 | $3,613 | |
| Sodium Chloride Sodium Chloride Irrig Solution | Brand | 25 | $2,990 | |
| Fesoterodine Fumarate Er Fesoterodine Fumarate | Brand | 17 | $1,625 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 42 billing codesPaid by Medicare
$80,209
Medicare patients
123
Services billed
8,551
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 71% | |
| High blood pressure | 69% | |
| Depression | 42% | |
| Diabetes | 30% | |
| Chronic kidney disease | 29% | |
| Osteoporosis | 28% | |
| Cancer | 23% | |
| Ischemic heart disease | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 35 | 8,100 | $39,432 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
70 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urology in Pennsylvania
Related records
Urology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Urology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.